A Phase 1, Multi-center, Open-label, Dose Finding Study of CC-92328 in Subjects With Relapsed and/or Refractory Multiple Myeloma

Celgene15 sites in 3 countries26 target enrollmentOctober 5, 2021

ConditionsMultiple Myeloma

InterventionsCC-92328

DrugsCC-92328

Overview

Phase: Phase 1
Intervention: CC-92328
Conditions: Multiple Myeloma
Sponsor: Celgene
Enrollment: 26
Locations: 15
Primary Endpoint: Maximum Tolerated Dose (MTD)
Status: Terminated
Last Updated: last year

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This Phase 1, first-in-human (FIH), clinical study of CC-92328 will explore the safety, tolerability and preliminary biological and clinical activity of CC-92328 as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM). The study will be conducted in two parts: monotherapy dose escalation (Part A) and monotherapy dose expansion (Part B).

Registry

clinicaltrials.gov

Start Date

October 5, 2021

End Date

June 18, 2024

Last Updated

last year

Study Type

Interventional

Study Design

Single Group

Sex

All

Investigators

Sponsor

Celgene

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Participants must satisfy the following criteria to be enrolled in the study:
•must understand and voluntarily sign an informed consent form (ICF) prior to any study-related assessments/procedures being conducted.
•willing and able to adhere to the study visit schedule and other protocol requirements.
•Participant is ≥ 18 years of age the time of signing the ICF.
•Participant has a history of multiple myeloma (MM) with relapsed and/or refractory disease who have failed or who are ineligible or intolerant to available therapies that may provide clinical benefit.
•Have documented disease progression on or within 12 months from the last dose of their last myeloma therapy.
•Participant must have measurable disease.
•Participant has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or
•Females of childbearing potential (FCBP) must commit to true abstinence from heterosexual contact or agree to use at least one method of highly effective contraception without interruption from screening to at least 12 weeks after the last dose of CC-92328
•Males must practice true abstinence or agree to use a condom

Exclusion Criteria

•The presence of any of the following will exclude a participant from enrollment:
•Participant has symptomatic central nervous system involvement of MM.
•Participant had a prior autologous stem cell transplant ≤ 90 days prior to starting CC-
•Participant had a prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 12 months prior to starting CC-
•Participant had prior systemic cancer-directed treatments or investigational modalities ≤ 5 half-lives or 4 weeks prior to starting CC-92328, whichever is shorter.
•Participant is a pregnant or lactating female.
•Participant received live virus vaccines within at least 4 weeks prior to starting study drug.
•Participant has known active human immunodeficiency virus (HIV) infection.
•Participant has active hepatitis B or C (HBV/HCV) infection.
•Participant weight is ≤ 40 kg at screening.

Arms & Interventions

Administration of CC-92328

CC-92328 administered intravenously in 28-day cycles

Intervention: CC-92328

Outcomes

Primary Outcomes

Maximum Tolerated Dose (MTD)

Time Frame: Up to 12 weeks after the last dose

Defined as the highest dose at which less than 33% of the population treated with CC-92328 experience a dose-limiting toxicity (DLT) in the first cycle and at least 6 evaluable participants have been treated at this dose level.

Incidence of Adverse Events (AEs)

Time Frame: Up to 12 weeks after the last dose

Type, frequency, seriousness, severity and relationship of AEs to CC-92328.

Dose-Limiting Toxicities (DLTs)

Time Frame: Up to 28 days after the first dose

Are defined as toxicities that meet the protocol-specified criteria occurring within the DLT assessment window (Cycle 1, Days 1 to 28) except those that are clearly and incontrovertibly due to the underlying disease or extraneous causes.

Secondary Outcomes

Pharmacokinetics - Cmax(Day 1 to 9 weeks after last dose of study drug)
Pharmacokinetics - t1/2(Day 1 to 9 weeks after last dose of study drug)
Frequency of Anti-CC92328 antibodies (ADA)(Day 1 to 9 weeks after last dose of study drug)
Preliminary Efficacy - Time to response(Up to approximately 2 years)
Preliminary Efficacy - Duration of response(Up to approximately 2 years)
Preliminary Efficacy - Overall Survival (OS)(Up to approximately 2 years)
Pharmacokinetics - CL(Day 1 to 9 weeks after last dose of study drug)
Pharmacokinetics - Vd(Day 1 to 9 weeks after last dose of study drug)
Presence of Anti-CC92328 antibodies (ADA)(Day 1 to 9 weeks after last dose of study drug)
Preliminary Efficacy - Overall Response Rate (ORR)(Up to approximately 2 years)
Preliminary Efficacy - Progression-free Survival (PFS)(Up to approximately 2 years)
Pharmacokinetics - tmax(Day 1 to 9 weeks after last dose of study drug)
Pharmacokinetics - AUC(Day 1 to 9 weeks after last dose of study drug)
Pharmacokinetics - Cmin(Day 1 to 9 weeks after last dose of study drug)
Pharmacokinetics - Accumulation index of CC-92328(Day 1 to 9 weeks after last dose of study drug)